Pharma Value

What Pharma Value does

Pharma Value is a Rome-based pharmaceutical regulatory affairs and market access consultancy serving pharmaceutical companies seeking to navigate Italian drug pricing and reimbursement procedures. Founded around 2013 by Valeria Viola as a sole proprietorship, the firm converted to a single-member limited liability company (Pharma Value Srl unipersonale) on 17 February 2023. With a team of approximately 18 specialists, the firm advises enterprise pharma clients on AIFA procedures, pricing negotiations, stakeholder mapping, and access strategy for both standard and rare disease therapies. Named clients include AstraZeneca, Alexion, Pierre Fabre, and ARS R. Marche.

The firm's core offering is professional consulting rather than a software product. Service lines include regulatory monitoring, scenario analysis, normative analysis, thematic insights, and in-house training. Analytical outputs include published research on Italian drug access timelines (e.g., 459-day national average and 62-day regional average for ultra-rare disease drugs) and co-authored reform proposals with the rare disease observatory OSSFOR. Pharma Value does not operate a proprietary technology platform; its infrastructure is built on standard business tools (WordPress, HubSpot, Google Analytics). Recent initiatives include the June 2026 launch of the Osservatorio Regional Access (ORA) project and ongoing poster presentations at ISPOR Europe 2025 and the GIRF National Congress.

Commercially, Pharma Value follows a sales-led, direct consultancy model with quote-based engagements tailored to enterprise pharmaceutical clients. Revenue is generated through professional services fees, with no publicly disclosed pricing or tiers. The firm operates exclusively in Italy (single-country, domestic market) and has no disclosed funding, no institutional investors, and no M&A activity. Marketing and demand generation rely on content marketing (blog, 'Pensierini' newsletter), social media presence (LinkedIn, Facebook, Instagram), conference participation (ISPOR, GIRF, PharmaTrend), and scientific publications in collaboration with partners such as Nomos Centro Studi Parlamentari.

Name

Pharma Value

Legal name

Pharma Value Srl unipersonale

Website

https://pharmavalue.it

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Pharma Value is a Rome-based pharmaceutical consulting firm specializing in regulatory affairs, market access strategy, and pricing and reimbursement advisory for pharmaceutical companies navigating the Italian AIFA system. Founded around 2013 by Valeria Viola, the 18-person firm serves enterprise pharma clients across Italy.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory and Market Access Consulting

NAICS

Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Pricing & Contracting Strategy (HLAIAKAA)

akta.pro secondary industries

Access Policy, Advocacy & Stakeholder Management (HLAIAKAL), Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC)

Keywords

• Pharmaceutical regulatory consulting
• Drug pricing reimbursement
• Market access advisory
• AIFA regulatory affairs
• Orphan drug access

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Regulatory and Consultancy Services: Professional services including regulatory monitoring, regulatory analysis, monitoring and stakeholder analysis, counseling on access strategies, and thematic insights related to drug pricing and reimbursement in Italy.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Pharma Value provides specialized consulting services to pharmaceutical companies seeking drug pricing and reimbursement access in Italy. Offerings include regulatory monitoring, normative and scenario analysis, stakeholder mapping, access strategy counseling, thematic insights, in-house training, and industry publications (such as the annual Agenda and joint AIFA reform reports with NOMOS). The firm helps clients obtain fair pricing and reimbursement by mediating between company profit, patient needs, and NHS resource constraints.

Product overview

Pharma Value is a pharmaceutical consulting company that provides regulatory affairs, market access, and policy advisory services to pharmaceutical companies seeking to navigate the Italian drug pricing and reimbursement landscape. Their offerings include scenario analysis, regulatory monitoring, stakeholder mapping, training services, and industry publications such as agendas and special reports. The company operates as a consulting services firm rather than a software product company.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory and Market Access Consulting Services Professional consulting services including regulatory monitoring, regulatory and normative analysis, monitoring and stakeholder analysis, scenario analysis, counseling on access strategies, and thematic insights to help pharmaceutical companies obtain fair pricing and reimbursement in Italy.
• Pensierini Newsletter Email newsletter providing regular thought leadership content on pharmaceutical policy, regulatory procedures, and market access topics; more than 13 editions have been published covering topics such as generics, experiences, procedures, money, failures, and conservatism.
• AIFA Governance Reform Special Reports Special reports produced in collaboration with Nomos Centro Studi Parlamentari analyzing AIFA governance reform and pharmaceutical regulatory developments, including Special No. 2 and No. 3 on AIFA reform.
• Pharmaceutical In-House Training Services Cross-functional in-house training delivered to pharmaceutical company teams on regulatory and market access topics; a notable session was conducted with AstraZeneca on 28 November 2024.

Quantifiable outcome

• 459 days average national access time for ultra-rare disease drugs analyzed in company research
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development Partner · 28 November 2024Organized an in-house training day with AstraZeneca on 28 November 2024, described as a unique cross-functional training experience of great innovative value.
• RarelabminorStrategic or Co-development Partner · 6 February 2024Collaboration on survey assessing the actual impact of comparator use in orphan drug price negotiations with AIFA.
• OSSFOR (Osservatorio Malattie Rare)coreStrategic or Co-development Partner · 31 January 2023Valeria Viola, owner of Pharma Value, participated in the 6th OSSFOR Annual Report 2022 presentation. Co-authored proposal for regulatory reform of 648/96 for orphan drug access with Pharma Value team members.
• Prospetti Soc. Coop.minorImplementation/ SI/ Consulting Partner · 1 January 2023Cooperation for evaluation and analysis of Pharma Value services, including customer feedback survey conducted starting January 2023.
• AlexionminorStrategic or Co-development Partner · 29 November 2022Collaboration on ISPOR poster presentation analyzing timing of access to drugs and advanced therapies (ATMP) for ultra-rare diseases. Partner representative Francesco Perrone co-authored the research with Pharma Value's Ginevra Mastroianni.
• Pierre FabreminorStrategic or Co-development Partner · 29 November 2022Collaboration on ISPOR poster presentation regarding ultra-rare disease drug access. Partner representative Marcello Girardini co-authored the research.
• ARS R. MarcheminorStrategic or Co-development Partner · 29 November 2022Research collaboration on analysis of timing of access to drugs and advanced therapies for ultra-rare diseases. Partner representative Andrea Marinozzi co-authored the ISPOR presentation.
• Nomos Centro Studi ParlamentaricoreStrategic or Co-development PartnerOngoing collaboration producing special reports analyzing AIFA governance reform and pharmaceutical regulatory developments. Multiple joint publications including Special No. 2 and No. 3 on AIFA reform.
• More Than Access (MA Provider SUMA)coreStrategic or Co-development PartnerRegular team building collaborations including events in Val di Fiemme (September 2022) and Palma de Mallorca (September 2025). Joint participation in industry events and conferences.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Lumanity: Pharma and life sciences consultancy with practices in market access, pricing, HTA, and medical affairs. Closely aligned with Pharma Value's value proposition of integrating evidence generation with pricing and access strategy.
• Alira Health: Boutique international healthcare consultancy covering market access, real-world evidence, and regulatory affairs with a European footprint including Italy. Comparable scale and service mix to Pharma Value with similar client base of pharma and medtech manufacturers.
• CBPartners: Specialized pricing, market access, and evidence strategy consultancy for pharmaceutical and biotech clients. Highly comparable boutique offering overlapping directly with Pharma Value's pricing & reimbursement dossier and access strategy work.

Broad incumbents

• Evidera (PPD/Thermo Fisher): Evidence-generation, HTA, and market access consultancy serving pharma clients globally. Comparable to Pharma Value's value dossier and HTA-aligned dossier work but at much larger scale and with broader service portfolio.
• PharmaLex (now part of Cencora): Global regulatory and market access consultancy serving pharma/biotech with pricing, reimbursement, and HTA services. Direct competitor to Pharma Value's core market access offering but with vastly broader geographic and service coverage, including Italy.
• Syneos Health Consulting: Clinical and commercial services firm with consulting practice covering market access, pricing, and brand strategy for pharma. Overlaps with Pharma Value on commercial access advisory but operates as a full-service commercial/clinical organization.
• Charles River Associates (Life Sciences): Global consulting firm with a Life Sciences practice advising on pricing, market access, and commercial strategy for pharma and medtech. Overlaps with Pharma Value on access strategy but operates as a generalist consultancy at much larger scale.
• IQVIA (Consulting & Market Access): Global life sciences services giant with significant market access, pricing, and real-world evidence practices including Italy. Indirectly comparable — represents the scaled-services competitor Pharma Value differentiates against via boutique specialization.

Others

• OSSFOR (Osservatorio Malattie Rare): Italian rare disease observatory that collaborates with Pharma Value on orphan drug access research and regulatory reform (648/96 proposals). Ecosystem partner rather than competitor; comparable given shared rare-disease and policy focus.

Regional players

• MA Provider (More Than Access / SUMA): Italian market access service provider and documented Pharma Value partner (joint team-building and conference participation). Directly comparable Italy-focused market access peer with overlapping client base in pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmavalue
• Instagraminstagram.com/pharmavalue.it

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Value